CervoMed's (CRVO) Neutral Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright has reiterated a neutral rating for CervoMed (NASDAQ:CRVO) with a target price of $11.00, indicating a potential upside of 4.66% from the previous close.
• Other analysts have varied opinions, with Canaccord Genuity raising its target from $21.00 to $27.00 and maintaining a buy rating, while the consensus price target across multiple analysts stands at $19.29.
• CervoMed reported a loss of $0.70 per share in its last earnings announcement, missing the consensus estimate, despite revenue of $1.76 million surpassing expectations.

CervoMed (NASDAQ:CRVO - Get Free Report)'s stock had its "neutral" rating reaffirmed by HC Wainwright in a report issued on Monday, MarketBeat Ratings reports. They presently have a $11.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 24.29% from the company's current price. HC Wainwright also issued estimates for CervoMed's Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.60) EPS, Q1 2026 earnings at ($0.73) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.53) EPS.

A number of other research analysts have also issued reports on the company. D. Boral Capital boosted their target price on CervoMed from $15.00 to $31.00 and gave the company a "buy" rating in a report on Monday, August 18th. Roth Capital reissued a "buy" rating and issued a $16.00 target price (down previously from $20.00) on shares of CervoMed in a report on Tuesday, August 12th. Chardan Capital reissued a "buy" rating and issued a $15.00 target price on shares of CervoMed in a report on Monday, August 11th. Finally, Canaccord Genuity Group boosted their target price on CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $19.29.

CervoMed Stock Performance

NASDAQ CRVO traded down $0.35 on Monday, reaching $8.85. The stock had a trading volume of 139,160 shares, compared to its average volume of 111,841. CervoMed has a 12-month low of $1.80 and a 12-month high of $20.63. The business's 50-day moving average price is $8.89 and its 200 day moving average price is $8.18. The stock has a market cap of $81.89 million, a P/E ratio of -3.39 and a beta of -0.72.

CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $1.45 million. On average, sell-side analysts predict that CervoMed will post -1.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AWM Investment Company Inc. acquired a new position in CervoMed during the first quarter worth $7,898,000. Woodline Partners LP acquired a new position in CervoMed during the fourth quarter worth $175,000. Jane Street Group LLC acquired a new position in CervoMed during the second quarter worth $414,000. Nuveen Asset Management LLC grew its holdings in CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock worth $97,000 after acquiring an additional 22,104 shares during the period. Finally, Nuveen LLC acquired a new position in CervoMed during the first quarter worth $312,000. Institutional investors and hedge funds own 25.15% of the company's stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.